Translate this page into:
Role of Scintimammography in the Evaluation of Response to Neo - Adjuvant Chemo - Radiotherapy in Cancer of Breast
Correspondence to: Dr. R. Krishnakumar, Prof and Head, Department of Nuclear Medicine, Cancer Institute (W.I.A),East Canal Bank Road, Gandhi Nagar, Adyar, Chennai 600 020, Tamil Nadu, India Tel: 91- 44 - 22350131, 22350241, Fax: 91- 44 - 24912085 E-mail:krishmanju12@yahoo.com
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Gene resistance is one of the major obstacles in the treatment of patients with chemotherapy. In this study we have tried to corroborate the wash out rates of Sesta Methoxy Iso Butyl Isonitrile (MIBI) from the tumour to the presence of Multi Drug Resistant (MDR) gene in the tumour cells. Method: 51 patients were included in the study before they began any treatment. We did a baseline scintimammography before any biopsy was done. A second scan was done a month after the completion of chemotherapy and radiotherapy. The wash out rates have been calculated in the pre and post scintimammogram. Result: We found that all our patients had wash-out rates greater than 60% and yet had responded clinically to the treatment regime. Conclusion: Discrepancy could be ascribed to heterogeneity of the tumours, subsets of cells expressing varying and multiple resistant mechanisms may co-exist. Reduced blood flow to the tumour could be held accountable for poor penetration of MIBI in patients.
